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Abstract
Purpose: To summarize the results of American Society for Radiation Oncology (ASTRO)’s
analysis of appropriate delivery of postoperative radiation therapy (RT) for endometrial cancer
using the RAND/University of California, Los Angeles (UCLA) Appropriateness Method, outline
areas of convergence and divergence with the 2014 ASTRO endometrial Guideline, and highlight
where this analysis provides new information or perspective.
Methods and materials: The RAND/UCLA Appropriateness Method was used to combine
available evidence with expert opinion. A comprehensive literature review was conducted and a
multidisciplinary panel rated the appropriateness of RT options for different clinical scenarios.
Treatments were categorized by the median rating as Appropriate, Uncertain, or Inappropriate.
Results: The ASTRO endometrial Guideline and this analysis using the RAND/UCLA Appropriateness Method did not recommend adjuvant RT for early-stage, low-risk endometrioid cancers
and largely agree regarding use of vaginal brachytherapy for low-intermediate and highintermediate risk patients. For more advanced endometrioid cancer, chemotherapy with RT is
supported by both documents. The Guideline and the RAND/UCLA analysis diverged regarding
use of pelvic radiation. For stages II and III, this analysis rated external beam RT plus vaginal
brachytherapy Appropriate, whereas the Guideline preferred external beam alone. In addition, this
analysis offers insight on the role of histology, extent of nodal dissection, and para-aortic nodal
irradiation; the use of intensity modulated RT; and management of stage IVA.
Conclusions: This analysis based on the RAND/UCLA Method shows signiﬁcant agreement with
the 2014 endometrial Guideline. Areas of divergence, often in scenarios with low-level evidence,
included use of external beam RT plus vaginal brachytherapy in stages II and III and external beam
RT alone in early-stage patients. Furthermore, the analysis explores other important questions
regarding management of this disease site.
Copyright ª 2016 the Authors. Published by Elsevier Inc. on behalf of the American Society for
Radiation Oncology. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).

Background
This document was prepared by a working group with
expertise in endometrial cancer designated by the American Society for Radiation Oncology (ASTRO). This
analysis presents scientiﬁc, health, and safety information
and may to some extent reﬂect scientiﬁc or medical
opinion. It is made available to ASTRO members and to
the public for educational and informational purposes
only. Any commercial use of any content in this analysis
without the prior written consent of ASTRO is strictly
prohibited.
Adherence to this analysis will not ensure successful
treatment in every situation. Furthermore, this analysis
should not be deemed inclusive of all proper methods of
care or exclusive of other methods of care reasonably
directed to obtaining the same results. The ultimate
judgment regarding the propriety of any speciﬁc therapy
must be made by the physician and the patient in light of all
circumstances presented by the individual patient. ASTRO

assumes no liability for the information, conclusions, and
ﬁndings contained in this analysis. In addition, this analysis
cannot be assumed to apply to the use of these interventions
performed in the context of clinical trials, given that clinical
studies are designed to evaluate or validate innovative approaches in a disease for which improved staging and
treatment are needed or are being explored.
This RAND/UCLA analysis was prepared on the basis
of information available at the time the working group
and multidisciplinary panel were conducting their
research and discussions on this topic. There may be new
developments that are not reﬂected in this document and,
that may, over time, be a basis for ASTRO to consider
revisiting and updating this analysis.

Introduction
Endometrial cancer is a common disease with
increasing incidence and yet considerable controversy
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regarding optimal therapy. Although randomized trials
address many important questions regarding radiation,
uncertainty remains because of patient and disease heterogeneity and numerous potential treatment strategies.
The most favorable stage I patients are often cured with
surgery alone. For higher risk early-stage patients, vaginal
brachytherapy or external beam radiation therapy (RT)
may be considered to improve local control, and systemic
therapy can potentially address occult distant metastasis
risk. For advanced-stage patients, the optimal regimen
and sequencing has yet to be determined and includes
chemotherapy and RT.
Reﬂecting the complexity of endometrial cancer
treatment decisions and ambiguity of available evidence
for many questions, ASTRO applied the RAND/University of California at Los Angeles (UCLA) Appropriateness Method to assess clinical scenarios and provide
management recommendations. Although this analysis
and ASTRO’s clinical practice guideline on endometrial
cancer1 focus on the same disease site, they differ in their
clinical questions, methodologies for assessing the literature, level of evidence considered, and subsequently
their recommendations. This executive summary brieﬂy
discusses areas of concordance and divergence between
the Guideline and the RAND/UCLA analysis and highlights where the analysis explores issues not covered in
the Guideline. The full analysis results are reported in the
Supplemental Materials.

Methods and Materials
Process
This analysis uses the RAND/UCLA Appropriateness
Method, developed in the 1980s to provide a formalized
way to “combine the best available scientiﬁc evidence
with the collective judgment of experts to yield a statement regarding the appropriateness of performing a procedure.”2 It has been applied internationally across
medical disciplines and uses a multidisciplinary panel to
rate wide-ranging clinical scenarios that physicians may
encounter in practice based on a comprehensive literature
review. The panel includes different clinical specialties
potentially involved in the care of the patients represented
in the scenarios and is designed to beneﬁt from collective
expertise and mitigate the tendency of physicians performing a procedure to rate it higher than those who do
not.3 For this analysis, the panel was composed of
members from radiation oncology, medical oncology,
gynecologic (GYN) oncology, medical physics, internal
medicine, and health services research. Primarily none
GYN-specialized radiation oncologists were used, based
on discussion with experts in the RAND/UCLA Method,
to potentially reduce bias.
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The process results in ratings of Appropriate, Uncertain, or Inappropriate for potential treatments for the
clinical scenarios. An Appropriate rating indicates predicted beneﬁts are sufﬁciently greater than risks to make
the intervention worth using. It is not intended to imply
the treatment must be used in all patients ﬁtting the scenario. Similarly, an Inappropriate rating shows projected
risks may outweigh beneﬁts but does not mean the
treatment should never be applied in that scenario. The
Uncertain rating reﬂects inconclusive evidence and/or a
lack of consensus regarding beneﬁts and risks.

Working group
The working group comprised radiation oncologists
with expertise in GYN cancers and/or the RAND/UCLA
Appropriateness Method. With ASTRO staff, the working
group developed the literature review, scenarios, and
deﬁnitions via conference call and e-mail and later
reconvened to interpret the ratings and write the ﬁnal
document.

Literature review
We searched MEDLINE PubMed and Trip Database
for English-language articles published between January
1970 and September 2012 evaluating women age 18
years with stages I to IV endometrial cancer of any
nonsarcoma histology who received vaginal brachytherapy, external beam RT, and/or intensity modulated RT
(IMRT), with or without chemotherapy. The electronic
searches were supplemented by hand searches. In total,
238 articles were included and data abstraction performed. Evidence tables and short literature summaries
were developed as resources for the panelists to reference
when rating the scenarios.

Scenarios and deﬁnitions
The working group identiﬁed factors likely to impact
decisions about appropriateness of radiation treatment,
from which scenarios were developed representing patients potentially encountered in practice and potential
radiotherapeutic options. Although these scenarios were
intended to address radiation speciﬁcally, the treatments
also covered chemoradiation. There were 1038 initial
scenarios and 698 second-round scenarios. A deﬁnition
list was produced to ensure common understanding of
terms among panelists.

Multidisciplinary panel
A multidisciplinary panel, representing radiation
oncology, medical oncology, GYN oncology, medical
physics, general GYN, internal medicine, and health
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Multidisciplinary panel members

Specialty

Name

Institution

Radiation oncology

Brett Cox (specialist in GU and CNS cancers)
Mitchell Kamrava (specialist in GYN cancers,
sarcomas, and brachytherapy)
Sunil Krishnan (specialist in GI cancers)
Joshua Lawson (general radiation oncologist)
Vicky Makker
D. Scott McMeekin
David Mutch
Craig Nielsen
Kimberly Peairs

North Shore-Long Island Jewish Health System
University of California, Los Angeles

Stanley Benedict
Michael Broder

University of California
Partnership for Health Analytic Research
(board-certiﬁed obstetrician-gynecologist)

Medical oncology
Gynecologic oncology
Internal medicine
Internal medicine/health
services research
Medical physics
Moderator

MD Anderson Cancer Center
Lexington Medical Center
Memorial Sloan Kettering Cancer Center
University of Oklahoma
Washington University
Cleveland Clinic
Johns Hopkins University

CNS, central nervous system; GI, gastrointestinal; GU, genitourinary; GYN, gynecologic.

services research was recruited. This multidisciplinary
composition is inherent to the process and intended to
achieve an objective perspective. As noted earlier, most
radiation oncologists selected were non-GYN specialists, which aimed to broaden the panel’s scope and
potentially decrease bias. Prospective panelists were
identiﬁed through ASTRO committees and outreach to
other medical specialty societies. Despite efforts to
include all planned specialties, the general gynecologist
was ultimately unable to participate. The ﬁnal 10member panel (Table 1) was chosen by the Best Practices Subcommittee and subsequently screened for
potential conﬂicts and bias.
For each scenario, panelists rated the treatment’s
appropriateness from 1 to 9 based on the literature review,
deﬁnitions, and their clinical judgment of an “average
patient” treated by an “average physician” in an “average
facility.” A “1” indicated much greater anticipated harms
than beneﬁts and a “9” much higher expected beneﬁts
than harms. A “5” signiﬁed balanced harms and beneﬁts
or that the rater felt unable to reach a conclusion. Panelists
were instructed not to consider cost or cost-effectiveness.
Before rating, panelists received an orientation to the
RAND/UCLA Method, the scenarios, and the evidence
tables, literature summaries, and deﬁnitions provided to
inform the rating; this approach enhanced consistency in
their methodology. The scenarios were rated iteratively in
2 rounds. The initial rating was conducted remotely and
independently via an online survey during March/April
2013. Next, at a face-to-face meeting, each panelist
received an individualized form showing the ratings per
scenario and the median and mean distance from the
median for the entire panel. Panelists discussed the scenarios, moderated by a methodologist experienced in the
RAND/UCLA Method, and then individually rerated
them using the same survey and process.

Ratings were analyzed using SAS statistical software.
Central tendency was measured using median because
responses were ordinal and the distance between scale
points not ﬁxed. Mean distance from the median
measured dispersion. Treatments were rated Inappropriate
for medians 1 to 3 (without disagreement), Uncertain for
medians 4 to 6 or if there was disagreement, and
Appropriate for medians 7 to 9 (without disagreement).
Disagreement was deﬁned as 3 ratings from 1 to 3 and
3 from 7 to 9 on the same scenario.

Results
Comparison of RAND/UCLA analysis and
endometrial guideline
Because ASTRO produced a Guideline on endometrial
cancer in 2014 and conducted this analysis within the
same time frame, we will brieﬂy summarize where they
agree and diverge.
Despite methodological differences, there is signiﬁcant
concordance (Table 2). This is reassuring and reﬂects the
substantial randomized data for some major questions.
For stage I endometrioid tumors, both documents
recommend against adjuvant RT for low-risk patients,
deﬁned in the RAND/UCLA analysis as grade 1 or 2
tumors with <50% myometrial invasion (MI), and no
lymphovascular space invasion (LVSI). For the highintermediate cohort, which included patients 70 years
with 1 risk factor (grade 2 or 3, outer-third MI, or LVSI),
50 years old with 2 risk factors, or any age with 3 risk
factors, there was consensus that vaginal brachytherapy is
the most appropriate treatment. Among low-intermediate
patients (50% MI but not high-intermediate), vaginal
brachytherapy was rated Uncertain to Appropriate. This
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Areas of concordance between Guideline and RAND/UCLA analysisa

Treatment

Guideline

RAND/UCLA analysis

No adjuvant radiation

Reasonable in patients with:

All radiation options rated Inappropriate for
stage I, low-risk patients

1. No residual disease in hysterectomy specimen
despite positive biopsy and
2. Grade 1 or 2 with no invasion or <50% MI
without other high-risk features.

Vaginal brachytherapy
alone

May be considered in patients with negative
node dissection and:
1. Grade 3 without MI and
2. Grade 1 or 2 with <50% MI and higher risk
features such as age >60 and/or LVSI

Preferred to pelvic radiation in patients with:

Rated appropriate for:
1. Stage I, low-intermediate risk, 10 nodes
dissected,
2. Stage I, high-intermediate risk, regardless of node
dissection, and
3. Stage II, low risk or low-intermediate risk, 10
nodes dissected

1. Grade 1 or 2 with 50% MI
2. Grade 3 with <50% MI

External beam radiation
therapy alone
(late stage)

Pelvic radiation without concurrent chemotherapy
may be considered based on pathologic risk for
pelvic recurrence for patients with:
1. Positive nodes and
2. Involved uterine serosa, ovaries/fallopian tubes,
vagina, bladder, or rectum

Chemoradiation

Concurrent chemoradiation followed by adjuvant
chemotherapy indicated for patients with:
1. Positive nodes and
2. Involved uterine serosa, ovaries/fallopian tubes,
vagina, bladder, or rectum

Alternative sequencing also acceptable.

Rated Uncertain or Appropriate in stages
IIIA-IIIC1
Pelvic plus para-aortic radiation rated
Appropriate for stage IIIC2

Although chemoradiation was not speciﬁcally
rated, VB rated Uncertain or Appropriate with
chemotherapy for stage I, high-intermediate
risk.
Pelvic RT þ VB rated Appropriate with
chemotherapy for:
1. Stage II, high-intermediate risk,
2. Stage IIIA if <10 nodes dissected and chemo
given concurrently, and
3. Stages IIIB and IIIC1

Pelvic and para-aortic RT  VB rated
Appropriate for stage IIIC2 with chemotherapy
High-intermediate risk, 70 years with 1 risk factor (grade 2 or 3, outer-third MI, or LVSI), 50 years old with 2 risk factors, or any age with 3 risk
factors; low-intermediate risk, any grade and 50% MI but not meeting the criteria for high-intermediate risk; low risk, grade 1 or 2, <50% MI, and
no LVSI; LVSI, lymphovascular space invasion; MI, myometrial invasion; RT, radiation therapy; VB, vaginal brachytherapy.
a
For the purpose of this comparison, histology was limited to endometrioid.

agrees with the Guideline, which recommended brachytherapy for deeply invasive grade 1 or 2 cancers or grade
3 tumors with <50% invasion and indicated brachytherapy may be considered for grade 3 cancer without invasion and grade 1 or 2 tumors with <50% invasion but
other high-risk features.
For stage II endometrioid cancers, the RAND/UCLA
analysis and Guideline both recommend pelvic RT,
although pelvic RT plus brachytherapy received the
highest ratings in the RAND/UCLA analysis. For stages
III and IV endometrioid tumors, both documents recommend combined chemoradiation when there are positive
nodes or involved uterine serosa/ovaries/fallopian tubes,
vagina, bladder, or rectum. Both also demonstrate less
enthusiasm for sandwich therapy than other chemotherapy and radiation sequences. RT was never rated

Appropriate with sandwich chemotherapy in the RAND/
UCLA analysis and the Guideline noted this regimen
delays RT, which may reduce local control and interrupts
chemotherapy.
There were also areas where the RAND/UCLA analysis and Guideline diverged (Table 3), perhaps reﬂecting
differences in their processes and the composition of the
groups determining the recommendations. Although the
Guideline panel comprised predominately GYNspecialized radiation oncologists, the RAND/UCLA
analysis used a multidisciplinary panel. This was intended
to mitigate potential for physicians to rate treatments they
deliver as more appropriate. Furthermore, a Guideline is
strictly evidence-based and relies on available literature to
make recommendations for predetermined “key questions.” The RAND/UCLA Method combines the best
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Areas of divergence between Guideline and RAND/UCLA analysisa

Treatment

Guideline

RAND/UCLA analysis

External beam radiation
alone(early stage)

May beneﬁt patients with:

Pelvic radiation alone rated Appropriate for:

1. Grade 3 with 50% MI or cervical stroma
invasion and
2. Grade 1 or 2 with 50% MI with other risk
factors, such as age >60 years and/or LVSI

1. Stage I, high-intermediate risk, no node
dissection and
2. Stage II, low-intermediate or highintermediate risk, 10 nodes dissected

Vaginal brachytherapy in patients undergoing
pelvic external beam radiation therapy may
not generally be warranted, unless risk
factors for vaginal recurrence are present

Rated Appropriate for:

External beam radiation therapy
plus brachytherapy

1. Stage I, high-intermediate risk, <10 nodes
dissected,
2. Stage II, and
3. Stage III

High-intermediate risk, 70 years with 1 risk factor (grade 2 or 3, outer-third MI, or LVSI), 50 years old with 2 risk factors, or any age with 3 risk
factors; low-intermediate risk, any grade and 50% MI but not meeting the criteria for high-intermediate risk; low risk, grade 1 or 2, <50% MI, and
no LVSI; LVSI, lymphovascular space invasion; MI, myometrial invasion.
a
For the purpose of this comparison, histology was limited to endometrioid.

evidence with collective expert opinion and addressed
many scenarios with limited current literature. Thus
panelists used their best judgment to reach conclusions.
The ability to focus on questions lacking literature is one
of this methodology’s strengths. However, the process is
not primarily designed to eliminate uncertainty and
Inappropriate, Uncertain, and Appropriate ratings have
equal value.
One area where the two documents differ is pelvic RT
in stage I endometrioid low- and high-intermediate risk
patients. The Guideline indicates that “[p]atients with
grade 1 or 2 tumors with 50% myometrial invasion may
also beneﬁt from pelvic RT to reduce pelvic recurrence
rates if other risk factors are present such as age >60
years and/or lymphovascular space invasion” based on
several randomized clinical trials showing decreased
pelvic failure with pelvic RT.1 The RAND/UCLA analysis rated vaginal brachytherapy Appropriate and pelvic
RT Uncertain for most scenarios. Although these recommendations appear discordant, this divergence reﬂects
a known controversy in the ﬁeld. The randomized trials
supporting pelvic RT have not demonstrated an overall
survival advantage and perhaps were underpowered to do
so. They also had varying inclusion criteria, degrees of
surgical staging, and receipt of vaginal brachytherapy.
Proponents of vaginal brachytherapy argue it is associated
with less toxicity than pelvic RT and the majority of
failures for uterine-conﬁned disease are vaginal. Many
factors must be considered in treatment recommendations
for this heterogeneous group, and the 2 documents reﬂect
that the evidence may support differing conclusions.
For stage II, the RAND/UCLA analysis rated pelvic
RT and brachytherapy Appropriate, whereas the Guideline recommended pelvic RT alone because of limited
evidence for adding brachytherapy. The Guideline speciﬁed brachytherapy may be indicated after pelvic RT in

early-stage patients with high-risk features for vaginal
recurrence, such as cervical involvement. Stage II is
deﬁned as involvement of cervical stroma and a recurring
theme during the moderated face-to-face panel discussion
was tailoring treatment to perceived risk, especially when
evidence was lacking. Panelists suggested vaginal
brachytherapy is likely to provide beneﬁt when assessment of cuff recurrence risk is high, pelvic RT when
nodal risk is high, and chemotherapy when systemic
failure risk is high. Absent level 1 evidence, panelists
rated vaginal brachytherapy with pelvic RT Appropriate
because of perceived vaginal cuff recurrence risk given
cervical involvement. In contrast, the Guideline is strictly
evidence-based and lacked data to support endorsing
vaginal brachytherapy. Its recommendation against
routine addition of vaginal brachytherapy is graded weak
and acknowledges that prospective data are lacking.
Again, what appear to be conﬂicting recommendations
highlight an area of controversy in the ﬁeld. Also,
although the RAND/UCLA analysis rated pelvic RT and
brachytherapy Appropriate more frequently than pelvic
RT alone, the latter was never rated Inappropriate.
For stages III or IV endometrioid tumors, both documents support chemotherapy and RT. Sequencing of the
treatments strongly affected the ratings in the RAND/
UCLA analysis, a trend not seen in the Guideline. The
analysis rated external beam RT and brachytherapy
Appropriate, whereas the Guideline recommended
external beam RT alone. The analysis’ ratings for stage III
disease reﬂect tailoring of radiation to perceived risk. The
panelists noted stage III is a very heterogeneous group
and the stage deﬁnition alone does not indicate presence
or absence of cervical involvement for stages IIIA and
IIIC. As for stage II, in no scenario (other than positive
para-aortic nodes) did the RAND/UCLA analysis rate
pelvic RT Inappropriate. The Appropriate ratings for
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vaginal brachytherapy and external beam likely reﬂect
panel discussions that cervical involvement warrants
consideration of brachytherapy. Less enthusiasm for
vaginal brachytherapy may have been seen if panelists
had rated stage IIIA and IIIC scenarios separately for
presence and absence of cervical involvement. Again, the
ratings reﬂect consensus decisions in the absence of
robust evidence.
By using a multidisciplinary panel moderated by a
specialist in the RAND/UCLA Method and including
noneGYN-specialized radiation oncologists, this analysis
was designed to limit biases. However, differences in
composition between the Guideline panel and the panel
for the RAND/UCLA analysis may account for divergences in recommendations. Panelists for the analysis
received a comprehensive literature summary to inform
ratings; however, the literature is dense and difﬁcult to
navigate for nonspecialists in GYN radiation oncology.
This is ASTRO’s ﬁrst analysis using the RAND/UCLA
Method, and a lesson learned was that the multidisciplinary panel may beneﬁt from greater disease-site
expertise when addressing complex topics such as management of endometrial cancer. It will remain unanswered
whether differences in panel composition would have
affected the ratings in this analysis.
The Guideline panel was tasked with providing strictly
evidence-based recommendations regarding key clinical
questions for which existing literature provided a framework. The working group for the RAND/UCLA analysis
had a broader mission that may be more reﬂective of

Table 4

Para-aortic radiation
Nodal dissection

Stage IVA

Areas of new perspective from the RAND/UCLA
analysis
There are several areas not addressed in the Guideline
where the RAND/UCLA analysis offers new perspective
(Table 4). These include the role of histology, para-aortic
nodal irradiation, and extent of nodal dissection; IMRT
versus 3-dimensional conformal RT (3D-CRT); and
management of stage IVA.
Effect of histology
The most inﬂuential pathologic feature for treatment
decisions is presence of uterine papillary serous or clear
cell histology, which represent only 10% to 15% of
endometrial cancer patients, but approximately half of
those with recurrence.4 There was extensive discussion
among panelists, who felt papillary serous and clear cell
tumors have signiﬁcant risk of systemic spread and warrant chemotherapy across all stages, and the role of radiation showed considerable uncertainty. There is

Areas of new perspective from the RAND/UCLA analysis

Papillary serous and clear
cell histologies

IMRT

day-to-day clinical practice and the struggles of making
recommendations in the absence of level 1 evidence.
However, both methodologies reached similar conclusions overall, particularly where relevant literature was
most robust. Areas of divergence reﬂect places where data
are limited and differing conclusions can fairly be
reached.

 Panelists concluded that these tumors have signiﬁcant metastasis risk and warrant chemotherapy across
all stages. Role of radiation showed uncertainty because of a lack of evidence.
 For stage I, vaginal brachytherapy with chemotherapy was
rated Appropriate for most scenarios.
 For stages II and III, vaginal brachytherapy plus pelvic radiation was rated Appropriate for the majority
of scenarios.
 Ratings indicated positive para-aortic basins should receive radiation, but negative nodes should not be
covered unless nodal dissection was insufﬁcient to rule out occult involvement.
 For stage I, ratings for vaginal brachytherapy alone increased in most scenarios with more extensive
nodal dissection.
 For stage II, pelvic radiation plus vaginal brachytherapy rated highest regardless of extent of nodal
dissection.
 For stage III, uncertainty about para-aortic radiation with no or <10 nodes dissected. After 10 nodes
dissected, para-aortic radiation rated Inappropriate except for pathologically involved nodes.
 Both 3D-CRT and IMRT rated Appropriate for scenarios where pelvic or para-aortic radiation is
indicated.
 Panelists cited most common setting for IMRT as treatment of para-aortic nodes.
 Stage IVA is a rare subset with locally advanced disease invading bladder and/or rectum. The Guideline
included stage IVA, but did not give speciﬁc recommendations.
 The analysis was restricted to
operable patients. Panelists indicated most stage IVA cases are unresectable and that the extent of
surgery may inﬂuence recommendations.
 Vaginal brachytherapy rated Inappropriate and remaining options Uncertain.

3D-CRT, 3-dimensional conformal radiation therapy; IMRT, intensity modulated radiation therapy.
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currently a paucity of randomized trials addressing radiation and chemotherapy for these histologies. For stage I,
vaginal brachytherapy with chemotherapy was rated
Appropriate, despite limited evidence. For stages II and
III, the panel rated combined pelvic RT and vaginal
brachytherapy as Appropriate.
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dissection. For stage II, the panel rated pelvic RT and
vaginal brachytherapy Appropriate regardless of extent of
dissection. Among stage III patients, there was some
uncertainty regarding adding para-aortic RT with no or
<10 nodes dissected. For 10 nodes dissected, panelists
rated para-aortic RT Inappropriate except for pathologically involved para-aortic nodes.

Para-aortic nodal RT
IMRT versus 3D-CRT
For stage III endometrioid cancers, pelvic RT with or
without vaginal brachytherapy was rated Appropriate for
most scenarios. The ratings indicated positive para-aortic
nodes should receive radiation but negative para-aortic
nodes should not be covered electively, unless nodal
dissection was insufﬁcient to rule out occult involvement
or postoperative computed tomography abdomen/pelvic
imaging reveals gross nodal disease. For stage IIIA and
IIIB endometrial cancer, regardless of histology, paraaortic RT was rated Uncertain or Inappropriate, trending
toward Inappropriate with more extensive nodal
dissection.
For endometrioid stage IIIC1 (pelvic node involvement), pelvic RT plus vaginal brachytherapy was rated
Appropriate. Pelvic RT alone was rated Uncertain to
Appropriate, depending on extent of nodal dissection or
use of chemotherapy. After node dissection, para-aortic
node RT was rated Inappropriate, but showed some uncertainty for no dissection. For endometrioid stage IIIC2
(para-aortic nodal involvement), RT targeting pelvic and
para-aortic nodes, with or without vaginal brachytherapy,
was rated Appropriate, and pelvic RT alone Inappropriate.
Across stage IIIC, vaginal brachytherapy alone was rated
Inappropriate, reﬂecting perceived maximal risk in the
pelvis. The plan for chemotherapy did little to change the
ratings.
The same themes were reﬂected for stage III papillary
serous or clear cell tumors, with RT directed based on
perceived risk. There was general agreement that stage III
papillary serous/clear cells should receive pelvic RT, with
or without vaginal brachytherapy, plus chemotherapy.
Coverage of pathologically involved para-aortic nodes
was rated Appropriate in stage IIIC. There was generally
greater uncertainty for stage III papillary serous/clear cell
cancers than for endometrioid tumors.
Effect of nodal dissection
Nodal dissection is the major surgical intervention
affecting adjuvant management. This is important for
both interpreting the literature and individual patient
management because of substantial heterogeneity in
lymph node sampling practice. For stage I, the panel
generally had greater conﬁdence in appropriateness of
vaginal brachytherapy alone with more extensive

IMRT use has increased signiﬁcantly for GYN cancers. Dosimetric studies indicate IMRT signiﬁcantly
reduces dose to critical normal structures, including
small bowel, bladder, rectum, and bone marrow.5
However, dosimetric parameters have been criticized
as not necessarily translating into meaningful clinical
endpoints, and IMRT can result in larger tissue volumes
treated to a low dose.6,7 Furthermore, because IMRT’s
more conformal dose distribution, tumor control could
be threatened by increased risk of compromised target
coverage.6
Although the literature suggests improved acute effects, data on late toxicity and efﬁcacy are promising but
limited.6,8,9 The panel rated both 3D-CRT and IMRT
Appropriate for scenarios where pelvic or para-aortic RT
is indicated and cited as the most common setting for
IMRT treatment of para-aortic lymph nodes, where
several critical structures make normal tissue sparing
particularly important. Some clinicians might also use a
hybrid approach, treating the pelvis with 3D-CRT and
encompassing para-aortic nodes using a nondivergent
matched IMRT ﬁeld. Although not reﬂected in the
ratings, panelists felt cost, insurance reimbursement,
technical capacity to plan and deliver IMRT, and concurrent chemotherapy inﬂuence decision-making.
Ongoing trials evaluating IMRT in GYN malignancies
should provide substantial information on its potential
advantages.
Stage IVA
Stage IVA endometrial cancer is a rare subset with
locally advanced disease invading bladder and/or rectum.
Although the Guideline included stage IVA, it did not
give speciﬁc recommendations in this setting. The
RAND/UCLA analysis was restricted to operable cases
and the panel noted most stage IVA is unresectable. They
indicated extent of surgery (radical hysterectomy vs
pelvic exenteration) may inﬂuence adjuvant radiation
recommendations. The panel rated vaginal brachytherapy
Inappropriate and the remaining options Uncertain in this
unusual setting. Management of stage IVA disease is very
individualized and requires close multidisciplinary
coordination.
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Conclusion
ASTRO produced both a Clinical Practice Guideline
and a RAND/UCLA analysis to address optimal management of endometrial cancer, a common and yet
controversial disease because of patient and disease
heterogeneity and many treatment strategies. Whereas
the Guideline relied strictly on available evidence and
was developed primarily by GYN-specialized radiation
oncologists, this analysis used the RAND/UCLA
Method to supplement current literature with collective
judgment from a multidisciplinary panel. These
different methodologies yielded both concordant conclusions and areas of divergence. Importantly, the
analysis also explored several topics not covered by the
Guideline. As ASTRO’s ﬁrst analysis based on
the RAND/UCLA Method, this project has offered
valuable lessons learned about how to best apply this
methodology to radiation oncology. It is hoped that
these 2 documents will prove valuable for clinicians
navigating this area of complicated decision-making
and inform future research by identifying evidence
gaps.
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